Johnson & Johnson (JNJ) concentration risks

The company's disclosed concentration profile is limited in scope, with two low-share exposures — one geographic and one product-level — that individually are unlikely to move the investment verdict. On the geographic side, approximately 23% of sales occurred in Europe, a low share of total Company sales, with a structural character that reflects where patients and healthcare systems are located rather than reliance on any individual counterparty. The product-level exposure is similarly contained: the company's largest product family, DARZALEX and DARZALEX FASPRO collectively, accounted for approximately 15.0% of total revenues in fiscal 2025, a low share by disclosed size. The structural character of this exposure reflects the product's established commercial position in the treatment of a specific patient population; while any single-product dependency creates some vulnerability to competitive entry or patent challenge, the low relative share limits the earnings impact of even a significant disruption. Taken together, neither exposure is at a level that would dominate the risk profile. There is no customer, supplier, or counterparty concentration disclosed alongside these geographic and product tilts. The overall profile suggests a company with broad revenue diversification across geographies and products, where the disclosed concentrations are informational disclosures rather than material single-point risk factors. Monitoring European healthcare policy and competitive dynamics around the flagship oncology franchise represents the relevant watch for these two exposures.

For the engine’s reasoning on JNJ’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.